引用本文:
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 728次   下载 102  
分享到: 微信 更多
半乳糖凝集素与静脉血栓形成机制的研究进展
张福厚
(昆明医科大学第一附属医院骨科,云南 昆明 650032)
摘要:
[摘要]半乳糖凝集素是一类糖结合蛋白,对细胞表面的半乳糖苷和细胞外的糖蛋白具有高度的亲和力.它们参与多种病理生理学过程,如:细胞凋亡、细胞活化和炎症的调节等,具有重要生物学功能.最近在对深静脉血栓(deep vein thrombosis,DVT)患者的对照实验研究中发现半乳糖凝集素-3结合蛋白(galectin-3 binding protein,Gal3Bp)可上调微粒(microparticles,MPs)的表达以促进DVT形成.P-选择素作为一种介导静脉血栓形成的糖蛋白,研究证明其有希望作为DVT诊断的一个生物标记物.半乳糖凝集素参与P-选择素的表达,并可能涉及静脉血栓的的形成.白细胞介素-6作为人体中一种重要的细胞因子,在炎症与静脉血栓栓塞症的研究中发现其可能是VT发生的一重要因素.研究表明半乳糖凝集素-3结合蛋白与半乳糖凝集素-3(galectin-3,Gal-3)可促进白细胞介素-6的表达以促进静脉血栓的形成.随着对半乳糖凝集素在炎症发生发展及静脉血栓形成过程中的研究不断深入,其有望成为防治静脉血栓的一个新的药物靶点及生物标记物,就此作一综述.
关键词:  [关键词]半乳糖凝集素  静脉血栓形成  炎症
DOI:
分类号:
基金项目:[基金项目]国家自然科学基金资助项目(81160236);云南省卫生科技计划项目(2014NS141)
Research Progress of Galectin in Mchanism of Venous Trombosis
ZHANG Fu-hou
(Dept. of Orthopedics,The 1st Affiliated Hospital ofKunming Medical University,Kunming Yunnan 650032,China)
Abstract:
[Abstract]Galectins are a family of carbohydrate-binding proteins that have a high affinity to galactosides on cell surfaces and extra cellular glycoproteins. They are involved in a variety of biological functions, including modulation of cell apoptosis, cell activation and inflammation. Our laboratory has recently identified galectin-3 binding protein(Gal-3BP)as being up-regulated in a microparticle proteomics analysis for deep venous thrombosis(DVT) patients compared to negative controls. P-selectin,another glycoprotein involved in thrombus propagation, has been proved as a promising target for DVT management and has been widely studied by our group. Galectins are involved in P-selectin expression and can potentially be implicated in the venous thrombogenesis process.Interleukin-6,as an important cytokine of body,which have been found in the study of inflammation for venous thromboembolism,may be an important factor for the frmation of VT. Research shows gal3bp:gal3 plays a critical role in VT, likely via IL-6 Promote thrombosis.The function of galectins, their role in inflammation and thrombosis as well as their potential implications as a new pharmacological target for DVT management are reviewed in this manuscript.
Key words:  [Key words]Galectin  Venous thrombosis  Inflammation